Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of pediatric laryngotracheobronchitis (croup) and results in close to 30,000 US hospitalizations each year [Ped. Inf. Dis. J. 20 (2001) 646]. No effective vaccine is available. We examined murine PIV-1 (Sendai virus, SeV) as a live,...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2004-08, Vol.22 (23), p.3182-3186
Main Authors: Slobod, Karen S, Shenep, Jerry L, Luján-Zilbermann, Jorge, Allison, Kim, Brown, Brita, Scroggs, Ruth Ann, Portner, Allen, Coleclough, Chris, Hurwitz, Julia L
Format: Article
Language:English
Subjects:
Administration, Intranasal
Adult
Amino acids
Animals
Antigen-Antibody Reactions
Applied microbiology
Biological and medical sciences
Chick Embryo
Cross Reactions
Dose-Response Relationship, Immunologic
Female
Fundamental and applied biological sciences. Psychology
Humans
Immunization
Immunogenicity
Infections
Intranasal murine parainfluenza virus
Laboratories
Male
Mice
Microbiology
Miscellaneous
Murine parainfluenza virus 1
Nasal Mucosa - immunology
Neutralization Tests
Parainfluenza Vaccines - adverse effects
Parainfluenza Vaccines - immunology
Parainfluenza Vaccines - therapeutic use
Parainfluenza virus
Parainfluenza Virus 1, Human - immunology
Paramyxovirus vaccines
Pediatrics
Respirovirus Infections - immunology
Respirovirus Infections - prevention & control
Sendai virus
Studies
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Attenuated - administration & dosage
Vaccines, Attenuated - adverse effects
Vaccines, Attenuated - immunology
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of pediatric laryngotracheobronchitis (croup) and results in close to 30,000 US hospitalizations each year [Ped. Inf. Dis. J. 20 (2001) 646]. No effective vaccine is available. We examined murine PIV-1 (Sendai virus, SeV) as a live, xenotropic vaccine for the closely related human PIV-1 in a phase I, dose escalation study in healthy adults. Intranasal Sendai virus was uniformly well-tolerated and showed evidence of immunogenicity in three of nine vaccinees despite pre-existing, cross-reactive immunity presumably induced by previous exposure to human PIV-1. Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2004.01.053